Literature DB >> 20967171

Plasma-derived versus recombinant factor VIII concentrates for the treatment of haemophilia A: plasma-derived is better.

Pier Mannuccio Mannucci1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2010        PMID： 20967171      PMCID： PMC2957495          DOI： 10.2450/2010.0072-10

Source DB:  PubMed          Journal:  Blood Transfus        ISSN： 1723-2007            Impact factor:   3.443


× No keyword cloud information.
  29 in total

Review 1.  The epidemiology of virus transmission by plasma derivatives: clinical studies verifying the lack of transmission of hepatitis B and C viruses and HIV type 1.

Authors:  E Tabor
Journal:  Transfusion       Date:  1999 Nov-Dec       Impact factor: 3.157

2.  Impact of inhibitor epitope profile on the neutralizing effect against plasma-derived and recombinant factor VIII concentrates in vitro.

Authors:  J Astermark; J Voorberg; H Lenk; D DiMichele; A Shapiro; G Tjönnfjord; E Berntorp
Journal:  Haemophilia       Date:  2003-09       Impact factor: 4.287

3.  Is the incidence and prevalence of inhibitors greater with recombinant products? Yes.

Authors:  L M Aledort
Journal:  J Thromb Haemost       Date:  2004-06       Impact factor: 5.824

4.  von Willebrand factor in factor VIII concentrates protects against neutralization by factor VIII antibodies of haemophilia A patients.

Authors:  A Kallas; T Talpsep
Journal:  Haemophilia       Date:  2001-07       Impact factor: 4.287

5.  Immune tolerance induction with highly purified plasma-derived factor VIII containing von Willebrand factor in hemophilia A patients with high-responding inhibitors.

Authors:  Frédérique Orsini; Chantal Rotschild; Philippe Beurrier; Albert Faradji; Jenny Goudemand; Benoît Polack
Journal:  Haematologica       Date:  2005-09       Impact factor: 9.941

6.  Influence of the type of factor VIII concentrate on the incidence of factor VIII inhibitors in previously untreated patients with severe hemophilia A.

Authors:  Jenny Goudemand; Chantal Rothschild; Virginie Demiguel; Christine Vinciguerrat; Thierry Lambert; Hervé Chambost; Annie Borel-Derlon; Ségolène Claeyssens; Yves Laurian; Thierry Calvez
Journal:  Blood       Date:  2005-09-15       Impact factor: 22.113

7.  Factor VIII inhibitor antibodies with C2 domain specificity are less inhibitory to factor VIII complexed with von Willebrand factor.

Authors:  T Suzuki; M Arai; K Amano; K Kagawa; K Fukutake
Journal:  Thromb Haemost       Date:  1996-11       Impact factor: 5.249

8.  Effect of clotting factors concentrates on lymphocyte and neutrophil function in vitro.

Authors:  Massimo Ghio; Paola Contini; Luciano Ottonello; Nicoletta Arduino; Alessandro Gringeri; Francesco Indiveri; Franco Dallegri; Francesco Puppo
Journal:  Thromb Haemost       Date:  2003-02       Impact factor: 5.249

Review 9.  The epidemiology of inhibitors in haemophilia A: a systematic review.

Authors:  J Wight; S Paisley
Journal:  Haemophilia       Date:  2003-07       Impact factor: 4.287

Review 10.  The role of plasma-derived factor VIII/von Willebrand factor concentrates in the treatment of hemophilia A patients.

Authors:  Günter Auerswald; Torsten Spranger; Hans-Hermann Brackmann
Journal:  Haematologica       Date:  2003-06       Impact factor: 9.941
View more
  15 in total

1.  Factor VIII inhibitor and source of replacement therapy.

Authors:  Pier Mannuccio Mannucci; Alessandro Gringeri; Elena Santagostino; Flora Peyvandi
Journal:  Blood Transfus       Date:  2011-09-21       Impact factor: 3.443

2.  Clinical and organisational aspects of haemophilia care: the patients' view.

Authors:  Gabriele Calizzani; Romano Arcieri
Journal:  Blood Transfus       Date:  2011-09-21       Impact factor: 3.443

Review 3.  Plasma and plasma-derived medicinal product self-sufficiency: the Italian case.

Authors:  Gabriele Calizzani; Samantha Profili; Fabio Candura; Monica Lanzoni; Stefania Vaglio; Livia Cannata; Liviana Catalano; Rosa Chianese; Giancarlo M Liumbruno; Giuliano Grazzini
Journal:  Blood Transfus       Date:  2013-09       Impact factor: 3.443

Review 4.  Present and future challenges in the treatment of haemophilia: the patient's perspective.

Authors:  Romano Arcieri; Angelo C Molinari; Stefania Farace; Giuseppe Mazza; Alberto Garnero; Gabriele Calizzani; Paola Giordano; Emily Oliovecchio; Lorenzo Mantovani; Lamberto Manzoli; Paul Giangrande
Journal:  Blood Transfus       Date:  2013-09       Impact factor: 3.443

Review 5.  The demand for factor VIII and for factor IX and the toll fractionation product surplus management.

Authors:  Gabriele Calizzani; Samantha Profili; Fabio Candura; Monica Lanzoni; Stefania Vaglio; Livia Cannata; Giancarlo M Liumbruno; Massimo Franchini; Pier Mannuccio Mannucci; Giuliano Grazzini
Journal:  Blood Transfus       Date:  2013-09       Impact factor: 3.443

Review 6.  Plasma-derived medicinal products self-sufficiency from national plasma: to what extent?

Authors:  Vincenzo De Angelis; Antonio Breda
Journal:  Blood Transfus       Date:  2013-09       Impact factor: 3.443

Review 7.  Factor VIII safety: plasma-derived versus recombinant products.

Authors:  Alessandro Gringeri
Journal:  Blood Transfus       Date:  2011-04-12       Impact factor: 3.443

8.  A role for von Willebrand factor in immune tolerance induction in patients with haemophilia A and inhibitors?

Authors:  Giovanni Di Minno; Antonio Coppola
Journal:  Blood Transfus       Date:  2011-05       Impact factor: 3.443

9.  Principles of treatment and update of recommendations for the management of haemophilia and congenital bleeding disorders in Italy.

Authors:  Angiola Rocino; Antonio Coppola; Massimo Franchini; Giancarlo Castaman; Cristina Santoro; Ezio Zanon; Elena Santagostino; Massimo Morfini
Journal:  Blood Transfus       Date:  2014-10       Impact factor: 3.443

Review 10.  Alloantibodies to therapeutic factor VIII in hemophilia A: the role of von Willebrand factor in regulating factor VIII immunogenicity.

Authors:  Johannes Oldenburg; Sébastien Lacroix-Desmazes; David Lillicrap
Journal:  Haematologica       Date:  2015-02       Impact factor: 9.941
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.